Precision BioSciences Ownership
| DTIL Stock | USD 4.74 0.09 1.94% |
Shares in Circulation | First Issued 2018-03-31 | Previous Quarter 6.9 M | Current Value 929.2 M | Avarage Shares Outstanding 34.8 M | Quarterly Volatility 172 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Precision | Build AI portfolio with Precision Stock |
Precision Stock Ownership Analysis
About 43.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.04. Some equities with similar Price to Book (P/B) outperform the market in the long run. Precision BioSciences recorded a loss per share of 2.87. The entity had not issued any dividends in recent years. The firm had 1:30 split on the 14th of February 2024. Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina. Precision Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 192 people. To learn more about Precision BioSciences call Michael Amoroso at 919 314 5512 or check out https://precisionbiosciences.com.Besides selling stocks to institutional investors, Precision BioSciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Precision BioSciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Precision BioSciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Precision BioSciences Quarterly Liabilities And Stockholders Equity |
|
Precision BioSciences Insider Trades History
About 11.0% of Precision BioSciences are currently held by insiders. Unlike Precision BioSciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Precision BioSciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Precision BioSciences' insider trades
Precision Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Precision BioSciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Precision BioSciences backward and forwards among themselves. Precision BioSciences' institutional investor refers to the entity that pools money to purchase Precision BioSciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2025-03-31 | 54.8 K | Dimensional Fund Advisors, Inc. | 2025-03-31 | 53.6 K | Northern Trust Corp | 2025-03-31 | 43 K | Moloney Securities Asset Management | 2025-03-31 | 42.9 K | Royal Bank Of Canada | 2025-03-31 | 40 K | Commonwealth Equity Services Inc | 2025-03-31 | 37.2 K | State Street Corp | 2025-03-31 | 22 K | Two Sigma Investments Llc | 2025-03-31 | 13.6 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 12.3 K | Aquilo Capital Management, Llc | 2025-03-31 | 726.1 K | Tang Capital Management Llc | 2025-03-31 | 673.3 K |
Precision BioSciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Precision BioSciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Precision BioSciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Precision BioSciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Precision BioSciences Outstanding Bonds
Precision BioSciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Precision BioSciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Precision bonds can be classified according to their maturity, which is the date when Precision BioSciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US740189AN56 Corp BondUS740189AN56 | View | |
| PRECISION CASTPARTS P Corp BondUS740189AP05 | View | |
| PRECISION CASTPARTS P Corp BondUS740189AH88 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.87) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.